Meeting Banner
Abstract #1381

Diagnostic Performance of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Peripheral MRA: Multicenter Comparison with DSA

Timothy Leiner1, Suzanne C. Gerretsen2, Thierry le Maire2, Stephan Miller3, Siegfried Thurnher4, Christoph U. Herborn5, Henrik J. Michaely6, Harald Kramer7, Angelo Vanzulli8, Josef Vymazal9, Martin Wasser10

1Radiology, Maastricht University Hospital, Maastrict, Netherlands; 2Radiology, Catharina Hospital, Eindhoven, Netherlands; 3Radiology, Eberhard-Karls University, Tbingen, Germany; 4Radiology, Hospital of St. John of God, Vienna, Austria; 5Radiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Institute of Clinical Radiology, University Hospital Mannheim, Mannheim, Germany; 7Radiology, Ludwig Maximilians University, Munich, Germany; 8Hospital Niguarda Ca Granda, Milan, Italy; 9Radiology, Na Homolce Hospital, Prague, Czech Republic; 10Radiology, Leiden University Medical Center, Leiden, Netherlands

Equivalent 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine were compared in terms of diagnostic performance in 397 segments from 96 patients with suspected peripheral arterial occlusive disease undergoing CE-MRA, using DSA as the reference standard. Three blinded readers rated the diagnostic performance of gadobenate dimeglumine significantly better in terms of sensitivity, specificity, and overall accuracy. In addition, significantly higher PPV and NPV values were noted after gadobenate dimeglumine compared to gadopentetate dimeglumine, despite the equivalent dose.